EP3708583
Ófúkósýleruð and-FGFR2IIIb mótefni
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
31.7.2014EP published:
2.3.2022EP application number:
19151147.6
EP translation filed:
7.4.2022Grant published:
15.5.2022EPO information:
European Patent Register
Max expiry date:
30.7.2034Expiry date:
30.7.2026Next due date:
31.7.2026
Title in English:
AFUCOSYLATED ANTI-FGFR2IIIB ANTIBODIESLanguage of the patent:
English
Timeline
Today
31.7.2014EP application
2.3.2022EP Publication
7.4.2022Translation submitted
15.5.2022Registration published
30.7.2026Expires
Owner
Name:
Five Prime Therapeutics, Inc.Address:
111 Oyster Point Boulevard, South San Francisco, CA 94080, US
Inventor
Name:
HARDING, ThomasAddress:
South San Francisco, CA 94080, US
Name:
PIERCE, KristenAddress:
South San Francisco, CA 94080, US
Name:
PATIL, NamrataAddress:
South San Francisco, CA 94080, US
Name:
BRENNAN, ThomasAddress:
South San Francisco, CA 94080, US
Name:
HAMBLETON, JulieAddress:
South San Francisco, CA 94080, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201361861198 PDate:
1.8.2013Country:
US
Number:
201361901732 PDate:
8.11.2013Country:
US
Number:
201461933632 PDate:
30.1.2014Country:
US
Classification
Categories:
C07K 16/28, A61K 31/337, A61K 31/513, A61K 33/24, A61K 39/395, A61P 1/00, A61P 43/00, A61K 39/00, A61P 35/00
Annual fees
Number
Paid
Expires
Payer
Number: 9
Paid: 25.7.2022
Expires: 30.7.2023
Payer: Árnason Faktor ehf.
Number: 10
Paid: 22.6.2023
Expires: 30.7.2024
Payer: Árnason Faktor ehf.
Number: 11
Paid: 19.6.2024
Expires: 30.7.2025
Payer: Árnason Faktor ehf.
Number: 12
Paid: 14.7.2025
Expires: 30.7.2026
Payer: Árnason Faktor ehf.